Evidence for the impact of interventions and medicines reconciliation on problematic polypharmacy in the UK: A rapid review of systematic reviews.
evidence-based medicine
health policy
overprescribing
polypharmacy
rapid review
systematic review
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
19
12
2019
revised:
14
02
2020
accepted:
27
04
2020
pubmed:
20
5
2020
medline:
29
7
2021
entrez:
20
5
2020
Statut:
ppublish
Résumé
This was a rapid review of systematic reviews (SRs) on problematic polypharmacy (PP) in the UK. The commissioner-defined topics were burden of PP, interventions to reduce PP, implementation activities to increase uptake of interventions, and efficient handover between primary and secondary care to reduce PP. Databases including Medline were searched to June 2019, SR quality was assessed using AMSTAR-2 (A MeaSurement Tool to Assess systematic Reviews) and a narrative synthesis was undertaken. Except for burden of PP (SRs had to include UK studies), there were no restrictions on country, location of care or outcomes. Nine SRs were included. On burden, three SRs (including six UK studies) found a high prevalence of polypharmacy in long term care. PP was associated with mortality, although unclear if causal, with no information on costs or health consequences. On interventions, six reviews (27 UK studies) found that interventions can reduce PP, but no effects on health outcomes. On handover between primary and secondary care, one review (two UK studies) found medicine reconciliation activities to reduce medication discrepancies at care transitions reduce PP, although the evidence is low quality. No SRs on implementation activities to increase uptake of interventions were found. SR quality was variable, with some concerns regarding meta-analysis methods. Evidence of the extent of PP in the UK, and what interventions to address it are effective in the UK, is limited. Future UK research is needed on the prevalence and consequences of PP, the effectiveness and cost-effectiveness of interventions to reduce PP, and barriers and activities to ensure uptake.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
42-75Subventions
Organisme : National Institute for Health Research Policy Research Programme (NIHR PRP)
ID : PR-PRU-1217-20401
Informations de copyright
© 2020 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Global Medicines Use in 2020. In: IMS Institute for Healthcare Informatics, Parsippany, NJ, 2015. Avaliable from https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/global-medicines-use-in-2020 [Accessed 1 December 2019].
Moody A, Mindell J, Faulding S, Neave A. Health Survey for England 2016. Prescribed medicines In: Health Survey for England: NHS Digital, 2017. Available from https://files.digital.nhs.uk/pdf/3/c/hse2016-pres-med.pdf [Accessed 25 November 2019].
Duerden M, Avery T, Payne R. Polypharmacy and medicines optimisation Making it safe and sound. In: The King's Fund, 2016. Available from https://www.kingsfund.org.uk/sites/default/files/field/field_publication_file/polypharmacy-and-medicines-optimisation-kingsfund-nov13.pdf [Accessed 25 November 2019].
NHS England. Clinical Pharmacists. In, No date Available from https://www.england.nhs.uk/gp/our-practice-teams/cp-gp/ [Accessed 25 November 2019].
Department of Health and Social Care. Matt Hancock orders review into overprescribing in the NHS. In, 2018. Available from https://www.gov.uk/government/news/matt-hancock-orders-review-into-over-prescribing-in-the-nhs [Accessed 25 November 2018].
NHS England. Social prescribing. In, No date. Available from https://www.england.nhs.uk/personalisedcare/social-prescribing/ [Accessed 14 February 2020].
Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. https://doi.org/10.1371/journal.pmed.1000097
Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. https://doi.org/10.1136/bmj.j4008
Johansson T, Abuzahra ME, Keller S, et al. Impact of strategies to reduce polypharmacy on clinically relevant endpoints: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(2):532-548.
Redmond P, Grimes TC, McDonnell R, Boland F, Hughes C, Fahey T. Impact of medication reconciliation for improving transitions of care. Cochrane Database Syst Rev. 2018;8(8):CD010791. https://doi.org/10.1002/14651858.CD010791.pub2
Gadsby R, Galloway M, Barker P, Sinclair A. Prescribed medicines for elderly frail people with diabetes resident in nursing homes-issues of polypharmacy and medication costs. Diabet Med. 2012;29(1):136-139.
Honney K, Trepte NJ, Parker RA, et al. Characteristics and determinants of survival in oldest old nursing home residents admitted to hospital with an acute illness compared to their younger counterparts. Aging Clin Exp Res. 2014;26(2):153-160.
Kua CH, Mak VSL, Huey Lee SW. Health outcomes of Deprescribing interventions among older residents in nursing homes: a systematic review and meta-analysis. J Am Med Dir Assoc. 2019;20:362-72.e11.
Whitney J, Close JCT, Lord SR, Jackson SHD. Identification of high risk fallers among older people living in residential care facilities: a simple screen based on easily collectable measures. Arch Gerontol Geriatr. 2012;55(3):690-695.
Parsons C, Johnston S, Mathie E, et al. Potentially inappropriate prescribing in older people with dementia in care homes: a retrospective analysis. Drugs Aging. 2012;29(2):143-155.
Clyne B, Fitzgerald C, Quinlan A, et al. Interventions to address potentially inappropriate prescribing in community-dwelling older adults: a systematic review of randomized controlled trials. J Am Geriatr Soc. 2016;64(6):1210-1222.
Barry PJ, Gallagher P, Ryan C, O'Mahony D. START (screening tool to alert doctors to the right treatment)--an evidence-based screening tool to detect prescribing omissions in elderly patients. Age Ageing. 2007;36(6):632-638.
Hill-Taylor B, Sketris I, Hayden J, Byrne S, O'Sullivan D, Christie R. Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact. J Clin Pharm Ther. 2013;38(5):360-372.
Hill-Taylor B, Walsh KA, Stewart S, Hayden J, Byrne S, Sketris IS. Effectiveness of the STOPP/START (screening tool of older Persons' potentially inappropriate prescriptions/screening tool to alert doctors to the right treatment) criteria: systematic review and meta-analysis of randomized controlled studies. J Clin Pharm Ther. 2016;41(2):158-169.
Byrne S, O'Mahony D, Hughes C, Parsons C, Patterson S, McCormack B, Finn F. An Evaluation of the Inappropriate Prescribing in Older Residents in Long Term Care Facilities in the Greater Cork and Northern Ireland Regions Using the STOPP and Beers' Criteria. 2011. Centre for Ageing Research and Development in Ireland. In, No date. Available from https://www.drugsandalcohol.ie/14878/ [Accessed 2 December 2019].
Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol. 2010;69(5):543-552.
Hearing SD, Wesnes K, Bowman CE. Beta blockers and cognitive function in elderly hypertensive patients: withdrawal and consequences of ACE inhibitor substitution. Int J Geriatr Psychopharmacol. 1999;2:13-17.
Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8(2):151-157.
Jokanovic N, Tan EC, Dooley MJ, Kirkpatrick CM, Bell JS. Prevalence and factors associated with polypharmacy in long-term care facilities: a systematic review. J Am Med Dir Assoc. 2015;16:535.e1-535.e12.
Ballard C, Lana MM, Theodoulou M, et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Med. 2008;5(4):e76.
Ballard CG, Thomas A, Fossey J, et al. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry. 2004;65(1):114-119.
Curran HV, Collins R, Fletcher S, Kee SC, Woods B, Iliffe S. Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life. Psychol Med. 2003;33(7):1223-1237.
Borrill Z, Roy K, Kolsum U, Southworth T, Vestbo J, Singh D. Seretide withdrawal increases airway inflammation in moderate COPD patients. Eur J Clin Pharmacol. 2009;65(11):1165-1166.
Choudhury AB, Dawson CM, Kilvington HE, et al. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir Res. 2007;8(1):93. https://doi.org/10.1186/1465-9921-8-93
Minett TS, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry. 2003;18(11):988-993.
Cunnington AL, White L, Hood K. Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson's disease. Parkinsonism Relat Disord. 2012;18(9):1051-1052.
Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association between polypharmacy and death: a systematic review and meta-analysis. J Am Pharm Assoc. 2003;57:729-38.e10.
Jarad NA, Wedzicha JA, Burge PS, Calverley PM. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group Respir Med. 1999;93:161-166.
Alsop K, Mac Mahon M. Withdrawing cardiovascular medications at a syncope clinic. Postgrad Med J. 2001;77(908):403-405.
Fotherby MD, Potter JF. Possibilities for antihypertensive drug therapy withdrawal in the elderly. J Hum Hypertens. 1994;8(11):857-863.
Jackson G, Martin E, McGing E, Cooper A. Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction. J Sex Med. 2005;2(4):513-516.
Sambu N, Dent H, Englyst N, et al. Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-Centre CESSATION study. Heart. 2011;97(20):1661-1667.
Esselinckx W, Doherty SM, Dixon AS. Polymyalgia rheumatica. Abrupt and gradual withdrawal of prednisolone treatment, clinical and laboratory observations. Ann Rheum Dis. 1977;36(3):219-224.
Fair JF. Supervised withdrawal of long-term digoxin therapy. Fam Pract. 1990;7(1):56-59.
Daly C, Edwards H. Withdrawal of digoxin in general practice in elderly patients. Ir Med J. 1983;76(1):19-20.
Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (screening tool of older Person's prescriptions) and START (screening tool to alert doctors to right treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(02):72-83.
Ballard C, Orrell M, YongZhong S, et al. Impact of antipsychotic review and nonpharmacological intervention on antipsychotic use, neuropsychiatric symptoms, and mortality in people with dementia living in nursing homes: a factorial cluster-randomized controlled trial by the well-being and health for people with dementia (WHELD) program. Am J Psychiatry. 2016;173(3):252-262.
Furniss L, Burns A, Craig SK, Scobie S, Cooke J, Faragher B. Effects of a pharmacist's medication review in nursing homes. Randomised controlled trial. Br J Psychiatry. 2000;176(6):563-567.
Patterson SM, Hughes CM, Crealey G, Cardwell C, Lapane KL. An evaluation of an adapted U.S. model of pharmaceutical care to improve psychoactive prescribing for nursing home residents in Northern Ireland (Fleetwood Northern Ireland study). J Am Geriatr Soc. 2010;58(1):44-53.
Zermansky AG, Alldred DP, Petty DR, et al. Clinical medication review by a pharmacist of elderly people living in care homes--randomised controlled trial. Age Ageing. 2006;35(6):586-591.
Fossey J, Ballard C, Juszczak E, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ. 2006;332(7544):756-761.
Jordan S, Gabe-Walters ME, Watkins A, et al. Nurse-led medicines' monitoring for patients with dementia in care homes: a pragmatic cohort stepped wedge cluster randomised trial. PLoS ONE. 2015;10(10):e0140203.
Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):583-623.
Rankin A, Cadogan CA, Patterson SM, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2018;9:CD008165. https://doi.org/10.1002/14651858.CD008165.pub4
Lenaghan E, Holland R, Brooks A. Home-based medication review in a high risk elderly population in primary care--the POLYMED randomised controlled trial. Age Ageing. 2007;36(3):292-297.
Pope G, Wall N, Peters CM, et al. Specialist medication review does not benefit short-term outcomes and net costs in continuing-care patients. Age Ageing. 2010;40:307-312.
Sturgess IK, McElnay JC, Hughes CM, Crealey G. Community pharmacy based provision of pharmaceutical care to older patients. Pharm World Sci. 2003;25(5):218-226.
Cadman B, Wright D, Bale A, et al. Pharmacist provided medicines reconciliation within 24 hours of admission and on discharge: a randomised controlled pilot study. BMJ Open. 2017;7(3):e013647. https://doi.org/10.1136/bmjopen-2016-013647
Bolas H, Brookes K, Scott M, McElnay J. Evaluation of a hospital-based community liaison pharmacy service in Northern Ireland. Pharm World Sci. 2004;26(2):114-120.